BCPAP
文献支持

BCPAP

收藏
  • ¥1800
  • EK-Bioscience已认证
  • CA-Y1064
  • 2025年07月14日
    avatar
    品牌商
    11钻石会员
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 文献和实验
    • 技术资料
    • 规格

      T25

    Bcpap/Bcpap细胞系/Bcpap细胞株/Bcpap人甲状腺癌乳头状细胞Cell line name B-CPAP

    Synonyms BC-PAP; BCPAP

    Accession CVCL_0153

    Resource Identification Initiative To cite this cell line use: B-CPAP (RRID:CVCL_0153)

    Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

    Part of: COSMIC cell lines project.

    Part of: TCGA-110-CL cell line panel.

    Population: Caucasian.

    Doubling time: ~30 hours (DSMZ=ACC-273).

    Microsatellite instability: Stable (MSS) (Sanger).

    Omics: Deep exome analysis.

    Omics: Deep quantitative proteome analysis.

    Omics: DNA methylation analysis.

    Omics: SNP array analysis.

    Omics: Transcriptome analysis by microarray.

    Omics: Transcriptome analysis by RNAseq.

    Caution: Originally classified a thyroid gland papillary carcinoma (PTC) but is now considered to be a poorly differentiated thyroid gland carcinoma (PDTC) (PubMed=23162534).

    Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.

    PubMed=1297527

    Paulin C., Fabien N., Fusco A., Pages M.-P., Patricot M.-C., Bornet H., Dubois P.-M.

    Description of a cell line established from a human thyroid papillary carcinoma and synthesizing human chorionic gonadotropin hormone.

    C. R. Acad. Sci. III, Sci. Vie 315:493-498(1992)

     

    PubMed=8156527; DOI=10.1002/1097-0142(19940415)73:8<2206::AID-CNCR2820730828>3.0.CO;2-M

    Fabien N., Fusco A., Santoro M.M., Barbier Y., Dubois P.-M., Paulin C.

    Description of a human papillary thyroid carcinoma cell line Morphologic study and expression of tumoral markers.

    Cancer 73:2206-2212(1994)

     

    PubMed=11439348; DOI=10.1038/sj.onc.1204531

    Frasca F., Vigneri P., Vella V., Vigneri R., Wang J.Y.-J.

    Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to hepatocyte growth factor.

    Oncogene 20:3845-3856(2001)

     

    PubMed=14522906

    Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.

    p73 tumor-suppressor activity is impaired in human thyroid cancer.

    Cancer Res. 63:5829-5837(2003)

     

    PubMed=15172756; DOI=10.1016/j.cancergencyto.2003.09.023

    Dettori T., Frau D.V., Garcia J.L., Pierantoni G.M., Lee C., Hernandez-Rivas J.M., Fusco A., Morton C.C., Vanni R.

    Comprehensive conventional and molecular cytogenetic characterization of B-CPAP, a human papillary thyroid carcinoma-derived cell line.

    Cancer Genet. Cytogenet. 151:171-177(2004)

     

    PubMed=17725429; DOI=10.1089/thy.2007.0097

    Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.

    Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.

    Thyroid 17:707-715(2007)

     

    PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026

    van Staveren W.C.G., Weiss-Solis D.Y., Delys L., Duprez L., Andry G., Franc B., Thomas G., Libert F., Dumont J.-E., Detours V., Maenhaut C.

    Human thyroid tumor cell lines derived from different tumor types present a common dedifferentiated phenotype.

    Cancer Res. 67:8113-8120(2007)

     

    PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569

    Schweppe R.E., Klopper J.P., Korch C.T., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A. 3rd, Smallridge R.C., Haugen B.R.

    Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

    J. Clin. Endocrinol. Metab. 93:4331-4341(2008)

     

    PubMed=19087340; DOI=10.1186/1471-2407-8-371; PMCID=PMC2651892

    Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.

    Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.

    BMC Cancer 8:371.1-371.11(2008)

     

    PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

    Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

    Signatures of mutation and selection in the cancer genome.

    Nature 463:893-898(2010)

     

    PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690; PMCID=PMC3229662

    Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.

    Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.

    Clin. Cancer Res. 17:7248-7264(2011)

     

    PubMed=22087789; DOI=10.1186/1755-8166-4-26; PMCID=PMC3248874

    Maric I., Viaggi S., Caria P., Frau D.V., Degan P., Vanni R.

    Centrosomal and mitotic abnormalities in cell lines derived from papillary thyroid cancer harboring specific gene alterations.

    Mol. Cytogenet. 4:26.1-26.8(2011)

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    该产品被引用文献

    *发表【中文论文】请标注:由上海酶研生物科技有限公司提供;

    *发表【英文论文】请标注:From Shanghai EK-Bioscience Biotechnology Co., Ltd.

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥1400
    上海盖宁生物科技有限公司
    2025年12月12日询价
    ¥1320
    博辉生物科技(广州)有限公司
    2025年12月05日询价
    ¥1300
    上海匹拓生物科技有限公司
    2025年12月18日询价
    ¥900
    安元生物科技(南京)有限公司
    2025年07月16日询价
    询价
    上海晶风生物科技有限公司
    2025年03月26日询价
    文献支持
    BCPAP
    ¥1800